Company Summary

Progen Pharmaceuticals Limited (ASX:PGL, OTC:PGLA) is a globally focused biotechnology company committed to improving patient outcomes through the discovery and development of small molecule-based cancer therapeutics.

Progen's core focus is development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The dual mechanism therapeutic approach focuses on both controlling tumour growth and spread.  

The company is also currently seeking divestment opportunities for its epigenetic assets.  

Our Structure

Progen Pharmaceuticals Limited is a publicly registered company trading on the Australian Securities Exchange and the US OTC Market (ASX:PGL; OTC:PGLA).

PharmaSynth Pty Ltd is a wholly owned subsidiary that operates a bio-pharmaceutical manufacturing business located in Brisbane, Australia.

PharmaSynth's website address is www.pharmasynth.com.au